Madecassoside improves insulin sensitivity in pancreatic cells to promote glucose‐stimulated insulin secretion (GSIS) and to enhance expression of insulin signalling proteins without any cytotoxic effects, making it a favourable drug compound in targeting type 2 diabetes mellitus.129. The gene discussed is INS; the disease is type 2 diabetes mellitus.